Larvol Veri

BIOMARKER:

MAP2K1 mutation

Entrez ID:

Related biomarkers:

‹

›

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

MAP2K1 mutation MAP2K1 mutation	Non Small Cell Lung Cancer NSCLC	lorlatinib Resistant: C3 – Early Trials lorlatinib Resistant : C3
MAP2K1 mutation MAP2K1 mutation	Ovarian Cancer Ovarian Cancer	selumetinib Sensitive: C4 – Case Studies selumetinib Sensitive : C4
MAP2K1 mutation MAP2K1 mutation	Melanoma Melanoma	dabrafenib Resistant: D – Preclinical dabrafenib Resistant : D
MAP2K1 mutation MAP2K1 mutation	Melanoma Melanoma	trametinib Resistant: D – Preclinical trametinib Resistant : D